Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation

— —

James Murrough (Associate Professor, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA) Dennis Charney (Biological psychiatrist and researcher, Icahn School of Medicine at Mount Sinai, New York, NY, USA)

Therapies for Treatment-Resistant Depression

Neuropharmacology and Neurostimulation

James Murrough (Associate Professor, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA), Dennis Charney (Biological psychiatrist and researcher, Icahn School of Medicine at Mount Sinai, New York, NY, USA)

$363.95

Paperback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Academic Press Inc
18 August 2025

Neurosciences; Toxicology (non-medical)

Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation provides readers with an authoritative, comprehensive and targeted treatment guide. The first section reviews the essential knowledge and methods of clinical neuroscience and neuropsychopharmacological techniques as they apply to novel treatment discovery for depression. This is followed by detailed chapters on ketamine, esketamine, other glutamate modulators in development, GABA modulators, neuropeptides, anti-inflammatory agents, and other classes of novel therapeutics under study for TRD and related mood disorders.

The last section consists of a set of chapters of special interest that includes current and future research directions, development of psilocybin-based interventions and other psychedelic compounds currently under study for TRD and advances in biomarker-guided and personalized treatment. Edited by world renowned experts in the field, this book is the ultimate resource for researchers and clinicians.

Edited by: James Murrough (Associate Professor Icahn School of Medicine at Mount Sinai (ISMMS) New York NY USA), Dennis Charney (Biological psychiatrist and researcher, Icahn School of Medicine at Mount Sinai, New York, NY, USA)
Imprint: Academic Press Inc
Country of Publication: United States [Currently unable to ship to USA: see Shipping Info]
Dimensions: Height: 235mm, Width: 191mm,
ISBN: 9780443160059
ISBN 10: 0443160058
Pages: 425
Publication Date: 18 August 2025
Audience: Professional and scholarly , Undergraduate
Format: Paperback
Publisher's Status: Active

1. Introduction 2. Treatment-Resistant Depression: Definitions, Epidemiology and Public Health Burden 3. Overview of Current Pharmacotherapy Options and Treatment Algorithms for TRD 4. From Novel Molecules to New Therapeutics for Mood Disorders: Pathways of Drug Discovery 5. Neuroimaging and Brain Based Biomarkers in Treatment-Resistant Depression 6. Inflammation and Peripheral Biomarkers in Treatment-Resistant Depression 7. Role of the Glutamate System in Treatment-Resistant Depression 8. Role of the GABA System in Treatment-Resistant Depression 9. Role of the Neuropeptides and Other Neuro-active Hormones in Treatment-Resistant Depression 10. Ketamine for Treatment-Resistant Depression: Discovery and Current Directions in Research and Clinical Care 11. Safety and Monitoring of Ketamine in Clinical Care 12. Development and Efficacy of Esketamine Treatment-Resistant Depression 13. Novel Glutamate Modulators in Development for Treatment-Resistant Depression 14. Brexanolone and Other GABA Modulators for Treatment-Resistant Depression 15. Special Topics: Psilocybin and Other Psychedelic Agents in Development for TRD 16. Special Topics: Role of Biomakers in Treatment Selection for Treatment-Resistant Depression 17. Special Topics: Current and Future Role of Genetics and Genomics in Treatment-Resistant Depression

I am Associate Professor with Tenure of Psychiatry and Neuroscience, and Director of the Depression and Anxiety Center for Discovery and Treatment (DAC) at the Icahn School of Medicine at Mount Sinai (ISMMS). My program of research utilizes molecular, neuroimaging, and experimental therapeutics approaches aimed at elucidating the fundamental mechanisms underlying stress-related disorders in humans, including major depressive disorder (MDD), posttraumatic stress disorder (PTSD) and anxiety disorders. The overall goal of my research is to advance the treatment of stress-related disorders through an enhanced understanding of disease pathogenesis and therapeutic mechanisms of action. Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's ""Top Medicine Scientists in the United States,"" with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.